Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics
Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics
Not yet recruiting · NCT07748364 · Registry updated 2026-08-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics | B-cell neoplasm, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, diffuse large B-cell lymphoma, histiocytosis, immune system disorder, immunoproliferative disorder, interdigitating dendritic cell sarcoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, mantle cell lymphoma, neoplasm, relapsed/refractory diffuse large B-cell lymphoma | Not yet recruiting | Phase 2 | 2026-08-05 | NCT07748364 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Genentech, Inc. | 221 |
| Joshua Brody | 2 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Icahn School of Medicine at Mount Sinai | New York | United States | 342 |